Pages that link to "Q38123941"
Jump to navigation
Jump to search
The following pages link to Hepatitis C virus reinfection following treatment among people who use drugs (Q38123941):
Displaying 50 items.
- The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention (Q26801456) (← links)
- Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review (Q27010548) (← links)
- Innate and Adaptive Immune Regulation During Chronic Viral Infections (Q28079717) (← links)
- APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. (Q30250088) (← links)
- Eligibility of persons who inject drugs for treatment of hepatitis C virus infection (Q30429470) (← links)
- Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV (Q33589224) (← links)
- Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response (Q33821728) (← links)
- Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. (Q33853664) (← links)
- Broadly neutralizing antibodies abrogate established hepatitis C virus infection (Q35032263) (← links)
- Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. (Q35628314) (← links)
- The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments (Q35750560) (← links)
- The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service (Q35839915) (← links)
- Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526. (Q35912053) (← links)
- Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. (Q36079786) (← links)
- Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. (Q36079814) (← links)
- Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence (Q36319803) (← links)
- Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era? (Q36579917) (← links)
- The hepatitis C treatment revolution: how to avoid Asia missing out (Q37098184) (← links)
- Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care (Q37358615) (← links)
- Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort (Q38192047) (← links)
- Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy (Q38566022) (← links)
- Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges. (Q38573508) (← links)
- Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. (Q38635796) (← links)
- Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study (Q38839753) (← links)
- Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs (Q38851684) (← links)
- Hepatic immunopathology during occult hepacivirus re-infection (Q40038615) (← links)
- Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. (Q40272763) (← links)
- Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. (Q40280603) (← links)
- Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection (Q40588780) (← links)
- Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs (Q40785885) (← links)
- Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study (Q40942161) (← links)
- Recommendations for the management of hepatitis C virus infection among people who inject drugs (Q41047662) (← links)
- Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care (Q41496602) (← links)
- Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? (Q41546485) (← links)
- T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee (Q42061089) (← links)
- Clinical outcomes in a cohort of anti-hepatitis C virus-positive patients with significant barriers to treatment referred to a Norwegian outpatient clinic (Q42240532) (← links)
- Recommendations for the management of hepatitis C virus infection among people who inject drugs. (Q42280296) (← links)
- Why is there still hepatitis C transmission in Australian prisons? A case report. (Q47138778) (← links)
- Knowledge of hepatitis C status moderates the relationship between history of drug treatment and sterile syringe use. (Q52558293) (← links)
- Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind. (Q52597000) (← links)
- Integrated Models of Care for People Living with Hepatitis C Virus and a Substance Use Disorder: Protocol for a Systematic Review. (Q54216905) (← links)
- Risk factors for familial clustering of hepatitis C virus infection in a Chinese Han population: a cross-sectional study. (Q55396689) (← links)
- A Guide to the Economics of Hepatitis C Virus Cure in 2017 (Q56654943) (← links)
- Drug consumption rooms (DCRs) as a setting to address hepatitis C - findings from an international online survey (Q57132633) (← links)
- Hepatitis C virus prevention and care for drug injectors: the French approach (Q57144432) (← links)
- HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era (Q58775051) (← links)
- Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice (Q59360780) (← links)
- Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report (Q59470836) (← links)
- Practical steps to improve chronic hepatitis C treatment in people with opioid use disorder (Q60632682) (← links)
- Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program (Q64095078) (← links)